RemeGen (HKG:9995, SHA:688331) obtained the approval of China's National Medical Products Administration to trial its novel antibody-drug conjugate (ADC) RC278 for injection, according to a Shanghai Stock Exchange filing on Tuesday.
The Chinese pharmaceutical company will test the drug as a treatment for advanced solid tumors, the filing said.
The company's Shanghai shares surged over 8% and Hong Kong shares soared 7% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.